TicoVac Vaccine Description
TicoVac is a whole virus vaccine containing the Tick-Borne Encephalitis (TBE) virus similar to the TBE virus found in nature. The virus is inactivated using formaldehyde, and therefore the vaccine cannot cause disease.
TicoVac induces neutralizing antibodies against the TBE virus, as the sequence and structure of the virus subtype match those found in nature.
Pfizer's TBE vaccine protects known subtypes of the TBE virus in both children (from one year of age) and adults, including the European, Siberian, and Far Eastern subtypes.
At Pfizer, Inc., we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines.
TicoVac Vaccine Indication
TicoVac is a vaccine indicated to prevent TBE in individuals 1 year of age and older.
TicoVac has been marketed in Europe under the brand name FSME-Immun. Pfizer's TBE vaccine has been protecting Europeans for over 40 years from TBE.
If you or your child have ever been infected with or been vaccinated against, Yellow fever, Japanese encephalitis, or Dengue viruses, tell your doctor. Antibodies might be in your blood that can react with the Tick-Borne Encephalitis (TBE) Virus used in tests to measure your antibody levels. These tests could then give wrong results.
The effect of TicoVac 0.5 ml during pregnancy or while breastfeeding is not known.
TicoVac Vaccine Dosage
TicoVac for individuals 16 years of age and older receive 0.5 ml suspension for injection in a prefilled syringe.
TicoVac Junior is for individuals 1 year of age to 15 years of age receive 0.25 ml.
TicoVac Vaccine News
February 23, 2021 - Pfizer application to FDA for Priority Review has been accepted. Tick-Borne Encephalitis (TBE) is a tick-borne viral infection that is endemic to Europe and Asia. TBE has been identified in more than 35 countries across Europe and Asia. However, it is not endemic in the U.S.
December 1, 2014 - Pfizer acquires Baxter's vaccine portfolio, including Neis Vac-C and FSME-IMMUN/TicoVac.
January 30, 2003 - Study: Tolerability of modified tick-borne encephalitis vaccine FSME-IMMUN “NEW” in children: results of post-marketing surveillance. These results demonstrated that, in routine medical practice, the FSME-IMMUN "NEW" vaccine at a dose of 1.2 microg antigen/0.25 ml is safe for the first vaccination in children.
TicoVac Vaccine Clinical Trials
Clinical Trial NCT00890422: Evaluation of Immunogenicity of Different Tick-Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine (immunization) - Last Update Posted on April 29, 2009
Clinical Trial NCT00894686: Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to the Second Booster in Children, Adolescents, and Young Adults - Last Update Posted on December 17, 2018
Clinical Trial NCT00161863: Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years - Last Update Posted in May 21, 2015